15 December 2023 : Original article
Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience
Masato Shizuku
123ABCDEF*, Nobuhiko Kurata 1B, Kanta Jobara 1B, Yasuhiro Fujimoto 1B, Yasuhiro Ogura 1ABCDFG
DOI: 10.12659/AOT.941456
Ann Transplant 2023; 28:e941456
Table 2 Clinical and pathological outcomes.
| Variables | Patients with pDSA | Patients without pDSA (n=97) | p | |
|---|---|---|---|---|
| Rituximab (+) (n=18) | Rituximab (−) (n=5) | |||
| Clinical outcomes | ||||
| Infusion reaction related with administration of Rituximab | 0 | n.a. | n.a. | n.a. |
| Other adverse events from administration of Rituximab to LT | 0 | n.a. | n.a. | n.a. |
| Bacteremia during hospitalization | 9 | 2 | 35 | 0.54 |
| CMV infection during hospitalization | 8 | 4 | 53 | 0.36 |
| Outcomes (death) | 3 | 0 | 17 | 0.62 |
| Detection of de novo DSA after LT | 1 | 0 | 0 | 0.06 |
| Pathological finding | ||||
| ACR (RAI ≥5) | 2 | 0 | 30 | 0.09 |
| AMR | 0 | 0 | 0 | n.a. |
| ACR – acute cellular rejection; AMR – antibody mediated rejection; DSA – donor specific antibody; LT – liver transplantation; n.a. – not available; pDSA – preformed donor specific antibody; RAI – rejection activity index. | ||||